
|Articles|September 12, 2022
Why eConsent Primes Studies & Patients for Success
Author(s)Medable
According to a survey conducted by Florence Healthcare, 47% of research sites had adopted eConsent by December 2020, just 8 months after the WHO declared an official pandemic. By July 2021, 75% of research sites had either used it or were looking into it. In conclusion - a decentralized consent process is here to stay. Learn why Medable's Total eConsent offering is the industry-leading remote consent technology, and how it can reduce your enrolment timelines by 50%.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Trending on PharmExec
1
Eli Lilly’s Oral Weight Loss Pill Prescribed Over 1,000 Times in First Days on Market
2
Eli Lilly Releases Updated Safety Data for Foundayo Following FDA’s Request
3
Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning
4
The Turning Point for Oral Biologics: Q&A With Morten Graugaard
5